Pentamycetin Ophthalmic Solution
Brand names,
Pentamycetin Ophthalmic Solution
Analogs
Pentamycetin Ophthalmic Solution
Brand Names Mixture
Pentamycetin Ophthalmic Solution
Chemical_Formula
C11H12Cl2N2O5
Pentamycetin Ophthalmic Solution
RX_link
http://www.rxlist.com/cgi/generic3/chloramphenicol.htm
Pentamycetin Ophthalmic Solution
fda sheet
Pentamycetin Ophthalmic Solution
msds (material safety sheet)
Pentamycetin Ophthalmic Solution
Synthesis Reference
No information avaliable
Pentamycetin Ophthalmic Solution
Molecular Weight
323.129 g/mol
Pentamycetin Ophthalmic Solution
Melting Point
150.5 oC
Pentamycetin Ophthalmic Solution
H2O Solubility
2500 mg/L (at 25 °C)
Pentamycetin Ophthalmic Solution
State
Solid
Pentamycetin Ophthalmic Solution
LogP
1.476
Pentamycetin Ophthalmic Solution
Dosage Forms
Capsule; Drops; Liquid; Ointment; Powder; Solution; Suspension; Tablet
Pentamycetin Ophthalmic Solution
Indication
Used in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.
Pentamycetin Ophthalmic Solution
Pharmacology
Chloramphenicol is a broad-spectrum antibiotic that was derived from the bacterium Streptomyces venezuelae and is now produced synthetically. Chloramphenicol is effective against a wide variety of microorganisms, but due to serious side-effects (e.g., damage to the bone marrow, including aplastic anemia) in humans, it is usually reserved for the treatment of serious and life-threatening infections (e.g., typhoid fever). Chloramphenicol is bacteriostatic but may be bactericidal in high concentrations or when used against highly susceptible organisms. Chloramphenicol stops bacterial growth by binding to the bacterial ribosome (blocking peptidyl transferase) and inhibiting protein synthesis.
Pentamycetin Ophthalmic Solution
Absorption
Rapidly and completely absorbed from gastrointestinal tract following oral administration (bioavailability 80%). Well absorbed following intramuscular administration (bioavailability 70%). Intraocular and some systemic absorption also occurs after topical application to the eye.
Pentamycetin Ophthalmic Solution
side effects and Toxicity
Oral, mouse: LD50 = 1500 mg/kg; Oral, rat: LD50 = 2500 mg/kg. Toxic reactions including fatalities have occurred in the premature and newborn; the signs and symptoms associated with these reactions have been referred to as the gray syndrome. Symptoms include (in order of appearance) abdominal distension with or without emesis, progressive pallid cyanosis, vasomotor collapse frequently accompanied by irregular respiration, and death within a few hours of onset of these symptoms.
Pentamycetin Ophthalmic Solution
Patient Information
No information avaliable
Pentamycetin Ophthalmic Solution
Organisms Affected
Enteric bacteria and other eubacteria